| P2093 | author name string | P F Halloran | |
| | T S Mele | |
| P2860 | cites work | Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report | Q78067669 |
| | Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx | Q82092762 |
| | Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity | Q93729850 |
| | Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol | Q43853463 |
| | Antitumor activity of mycophenolic acid | Q44276016 |
| | Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells | Q45212967 |
| | RS-61443--a new, potent immunosuppressive agent | Q45300416 |
| | T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. | Q45807697 |
| | A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. | Q46186465 |
| | FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group | Q46311487 |
| | Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration | Q46363542 |
| | Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion | Q47926348 |
| | Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept | Q47940101 |
| | Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. | Q52979941 |
| | FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. | Q52998120 |
| | Mycophenolate mofetil in pancreas transplantation. | Q53352257 |
| | Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. | Q53961304 |
| | Immunosuppressive effect of mycophenolic acid. | Q54068287 |
| | Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. | Q54143540 |
| | The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants | Q54275853 |
| | Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. | Q54296088 |
| | Cyclosporin in therapeutic doses increases renal allograft vascular resistance. | Q54423897 |
| | Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression | Q57377991 |
| | A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1 | Q57704207 |
| | A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION | Q57985174 |
| | Mycophenolic Acid: an Anti-cancer Compound with Unusual Properties | Q58979200 |
| | LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2 | Q62619859 |
| | Treatment Of Psoriasis With Oral Mycophenolic Acid | Q67340776 |
| | RS-61443--a phase I clinical trial and pilot rescue study | Q67513704 |
| | RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection | Q67568290 |
| | Mycophenolic acid: antiviral and antitumor properties | Q68588759 |
| | Bioavailability improvement of mycophenolic acid through amino ester derivatization | Q68719426 |
| | A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group | Q71588915 |
| | The impact of an acute rejection episode on long-term renal allograft survival (t1/2) | Q72354298 |
| | Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients | Q72659857 |
| | The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients | Q72835764 |
| | Mycophenolate mofetil rescue therapy in liver transplant recipients | Q73278349 |
| | Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation | Q73838383 |
| | Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up | Q73869017 |
| | A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study G | Q73944557 |
| | Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings | Q73949421 |
| | Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine | Q74015510 |
| | Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation | Q74528702 |
| | Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group | Q74616034 |
| | Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group | Q74685840 |
| | Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation | Q74686248 |
| | Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report | Q74725306 |
| | Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients | Q74812507 |
| | Chronic renal allograft rejection: no response to mycophenolate mofetil | Q77168149 |
| | Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation | Q77859751 |
| | Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid | Q27733135 |
| | Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. | Q33328295 |
| | Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice | Q33388349 |
| | Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes | Q33747600 |
| | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report | Q34187619 |
| | Tacrolimus rescue therapy for renal allograft rejection--five-year experience | Q34315266 |
| | How one thing has led to another | Q34500421 |
| | Selectins: interpreters of cell-specific carbohydrate information during inflammation | Q35532358 |
| | Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes | Q36135275 |
| | Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation | Q39356548 |
| | Tumors of the immunocompromised patient | Q39641413 |
| | Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety | Q39717156 |
| | Reduction of Ribonucleotides | Q39805408 |
| | Control of phosphoribosylpyrophosphate synthesis in human lymphocytes | Q40096806 |
| | Acute rejection and renal allograft outcome. | Q40448263 |
| | Human type I and II IMP dehydrogenases as drug targets | Q40621156 |
| | Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. | Q40834086 |
| | The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens | Q41071410 |
| | Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s | Q41137943 |
| | A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation | Q41484092 |
| | Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion | Q41698111 |
| | A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients | Q42411675 |
| | Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups | Q42551535 |
| | Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance | Q42818302 |
| | The inhibition of nucleic acid synthesis by mycophenolic acid | Q42934028 |
| | Risk factors for chronic rejection in renal allograft recipients. | Q43669281 |
| | Early versus late acute renal allograft rejection: impact on chronic rejection. | Q43824714 |
| P433 | issue | 2-3 | |
| P304 | page(s) | 215-245 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Immunopharmacology | Q24031542 |
| P1476 | title | The use of mycophenolate mofetil in transplant recipients | |
| P478 | volume | 47 | |